Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Disitamab Vedotin + Sintilimab in Elderly HER2+ Gastric Cancer
NCT05720533Phase 2Unknown
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2023
- Primary completion
- Mar 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
01
Overview
A Phase 2 trial of disitamab vedotin, sintilimab in gastric cancer (GC), sponsored by Tianjin Medical University Cancer Institute and Hospital. Status: unknown.
02
Drugs
disitamab vedotinsintilimab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT05720533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05720533.